Molecular Pathways in Cancer Are Increasingly Being Exploited

TON November 2015 Vol 8 No 6 - Personalized Medicine
Wayne Kuznar

Molecular pathways in cancer can be exploited for therapy, and sensitizing genetic aberrations are the ideal targets, said Alex Adjei, MD, PhD, at PMO Live 2015, the annual joint meeting of the Global Biomarkers Consortium and the World Cutaneous Malignancies Congress.1

Cancer cells have to evade a number of stresses to grow. They are complex and live in a toxic environment, but somehow they manage to survive.

All of the cancer driver genes can be classified into ≥1 of 12 signaling pathways thought to confer a selective growth advantage. These pathways can themselves be further organized into 3 core cellular processes (cell survival, cell fate, and genome maintenance).Multiple agents currently in the clinic attack most of these pathways.

The RAS-RAF-MEK-ERK pathway is an important mitogen-activated protein kinase pathway that is evolutionally conserved across species. It is activated by a variety of growth factors and cytokines, including epidermal growth factor, insulin-like growth factor, and transforming growth factor. These growth factors activate RAS through conversion of the inactive guanosine diphosphate–bound form to the active guanosine triphosphate–bound form. Activated RAS recruits RAF kinase to the membrane, where it is activated by phosphorylation, which, in turn, phosphorylates and activates MEK kinase. MEK kinase phosphorylates and activates ERK kinase; phosphorylated ERK can translocate to the nucleus and phosphorylate and activate transcription factors.

Aberrant activation of the RAS-RAF-MEK-ERK pathway occurs in >30% of human cancers. “Over the last 10 or 15 years, we have really tried to target all aspects of this pathway,” said Dr Adjei, Professor and Chair, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY. In particular, MEK1/2 inhibitors appeared to be an attractive therapeutic strategy targeting this pathway.

However, “if you looked at most of these agents in most of our solid tumors, they haven’t worked very well,” he said. “We get a few responses in selected cases, but if you think about what we thought about these pathways, and their importance in cancer, and the excitement when these agents came to the clinic, they haven’t turned out to be so.” Part of the reason is the cross talk between pathways that promotes activation of other pathways via a feedback loop.

What accounts for the lack of strong therapeutic activity of MEK inhibitors in early-stage clinical trials? Feedback inhibition of ERK on RAF is abrogated by MEK inhibitors, explained Dr Adjei, leading to activation of MEK independent of downstream RAF targets and resistance to apoptosis. This phenomenon may explain the lack of activity of single-agent MEK inhibition in many tumors.

“We hypothesized that a MEK inhibitor should synergize with a BRAF inhibitor,” said Dr Adjei.

BRAF mutations are observed in 2% to 3% of lung cancers, he said. More than half of the mutations are V600E hotspot mutations, and 43% are non-V600E mutations distributed in narrow areas between codons 594 and 606 on exon 15, and between 446 and 449 on exon 11.

In non–small-cell lung cancer (NSCLC), the pattern of BRAF mutations is dependent on the stage of the disease. Mutations in V600E are more abundant in advanced stages of NSCLC compared with local disease. Patients with NSCLC with BRAF V600E mutations have significantly worse disease-free survival and overall survival (OS) compared with patients with wild-type disease. When considering all potential BRAF mutants, however, patients with advanced lung cancer who harbor V600 mutations have improved OS compared with patients with non-V600 mutations.

In patients with BRAF V600E–mutant advanced NSCLC, single-agent dabrafenib is associated with an overall response rate (ORR) of 32%, and is relatively well-tolerated, according to phase 2 data released at the European Society for Medical Oncology 2014 Congress.2 Combining trametinib with dabrafenib increases the ORR to 63%.

Aberrations in RET
The rearranged during transfection (RET) gene resides on chromosome 10. It has a ligand called glial cell line–
derived neurotrophic factor (GDNF), which has its own receptor. RET activation requires the formation of a trimeric complex that includes the ligand, a GDNF-family receptor-alpha protein, and RET.

Historically, RET aberrations have been associated with thyroid cancers. Somatic and germline point mutations occur in sporadic and familial medullary thyroid cancers, respectively. RET fusions are found in papillary thyroid cancers. The frequency of RET aberrations in unselected NSCLCs is low at about 2%, said Dr Adjei.

Cabozantinib inhibits multiple targets, including RET, and was studied in 20 patients with advanced RET-rearranged lung cancers.3 Because cabozantinib is relatively toxic, 60% of patients in the study had to have dosages reduced. The best response was a partial response in 33%. Stable disease rate was 72%. The median progression-free survival was 7 months, and median OS was not reached.

Oncogenic Mutations: Only Some Are Predictive
Not all “oncogenic” mutations are predictive biomarkers, said Dr Adjei. PIK3CA is one mutation that was predictive of response to PIK3CA kinase inhibition in a primary human NSCLC tumor-derived xenograft. In contrast, double mutation with PIK3CA and KRAS was not sensitive. Likewise, an NSCLC tumor-derived xenograft with wild-type PIK3CA and KRAS, BRAF, and PTEN mutations was resistant to PIK3CA kinase inhibition. However, primary human breast tumor–derived xenografts with wild-type PIK3CA and KRAS, BRAF, and PTEN mutation were sensitive in vivo.

The lesson is that there are a number of oncogenes in which certain mutations might be sensitive, such as PIK3CA, but some cancers with a variety of mutations may be resistant. “Clearly, the [PIK3CA] pathway is more complicated, and if you are going to study it, we have to be able to tease out the ones that might actually benefit,” he explained.

Comprehensive molecular profiling by the Cancer Genome Atlas Research Network indicates that the magnitude of genomic rearrangement in lung cancer is large.4 Profiling of 230 resected lung adenocarcinomas revealed
significant mutation of 18 genes, including RIT1-activating mutations, and 31 cases that were previously classified as wild type were found to be oncogene positive.

About 140 genes can promote tumorigenesis when altered by intragenic mutations.5 A typical tumor contains 2 to 8 of these driver mutations, which can be classified into 12 core pathways. “Folks have tried to come up with different algorithms, one being that if you have the same codon mutated in at least 2 different tumors, then by definition it might be an oncogene,” Dr Adjei said. Activated genes that promote growth are probably 10% of the driver genes.

“One of the problems we have is that the most common aberrations are actually the tumor suppressor genes [ie, p53 and PTEN]…the problem is that with our current technology, we can’t target those because those genes are deleted…and we don’t have ways of putting them back,” he said.

References
1. Adjei A. Exploring molecular pathways in cancer. Presented at: PMO Live; July 22-25, 2015; Seattle, WA.
2. Planchard D, Kim T, Mazières J, et al. Dabrafenib in patients with BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): a multicenter, open-label, phase II trial (BRF113928). Presented at: European Society for Medical Oncology 2014 Congress; September 26-30, 2014; Madrid, Spain. http://oncologypro.esmo.org/Meeting-Resources/ESMO-2014/NSCLC-Metastat ic/Dabrafenib-in-patients-with-BRAF-V600E-mutant-advanced-non-small-cell-lung-cancer-NSCLC-A-multi center-open-label-phase-II-trial-BRF113928. Accessed September 25, 2015.
3. Drilon AE, Sima CS, Somwar R, et al. Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers. J Clin Oncol. 2015;33:abstract 8007.
4. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543-550.
5. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339:1546-1558.

Related Items
NCCN Updated Guideline Adds Treatment Options for HER2-Positive Breast Cancer, Emphasizing CDK4/CDK6 Inhibition in Hormone-Sensitive Disease
Wayne Kuznar
TOP Web Exclusives published on August 15, 2018 in NCCN News
NCCN Issues First Guideline for Immunotherapy-Related Adverse Events
Wayne Kuznar
JHOP Web Exclusives published on August 10, 2018 in Immunotherapy
Regorafenib Dose-Escalation Strategy Potentially a New Standard in Metastatic Colorectal Cancer
Wayne Kuznar
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Colorectal Cancer
Immunotherapy Combination Shows Durable Responses in Mismatch Repair–Deficient Metastatic Colorectal Cancer
Wayne Kuznar
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Immunotherapy
A Dynamic FDA Has Led to More Rapid Cancer Drug Development
Wayne Kuznar
JHOP Web Exclusives published on July 17, 2018 in FDA Approvals, News & Updates
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates & News, ASH
Quizartinib Combinations Show High Activity in Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates & News
Selecting Optimal Therapy for Chronic Lymphocytic Leukemia Is a Work in Progress
Wayne Kuznar
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Leukemia
Cediranib-Based Combination Therapy Extends Progression-Free Survival in Relapsed Ovarian Cancer
Wayne Kuznar
TOP - November 2017, Vol 10, No 4 published on November 13, 2017 in Gynecologic Cancers, Online First
Olaparib First PARP Inhibitor to Show Advantage in BRCA-Positive Breast Cancers
Wayne Kuznar
TOP - November 2017, Vol 10, No 4 published on November 13, 2017 in Breast Cancer
Last modified: November 20, 2015